| IPO Company Profile |
| Current Quote | News | SEC Filings | Peer IPO Companies |
| Vysis, Inc. |
| 3100 Woodcreek Drive, Downers Grove, IL 60515 * (630) 271-7000 |
| The company is a leading Genomic Diagnostics company that develops, commercializes and markets clinical products that provide information critical to the evaluation and management of cancer, prenatal disorders and other genetic diseases. |
| Manager | Tier | Phone |
| Furman Selz Incorporated | Lead Manager | (212) 309-8285 |
| Deutsche Morgan Grenfell | Co-manager | (212) 469-5600 |
| Everen Securities, Inc. | Co-manager | (312) 574-6859 |
| NASNTL: | VYSI | Manufacturing: | SIC 2835 | |
| Type of Shares: | Common Shares | Filing Date: | 10/17/97 | |
| U.S. Shares: | 3,000,000 | Offer Date: | 2/4/98 | |
| Non-U.S. Shares: | 0 | Filing Range: | $13.00 - $15.00 | |
| Primary Shares: | 3,000,000 | Offer Price: | $12.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.84 | |
| Offering Amount: | $42,000,000 | Selling: | $0.50 | |
| Expenses: | $0 | Reallowance: | $0.10 | |
| Post-IPO Shares: | 9,501,260 | |||
| Spin out parent firm: | Amoco Corporation | |||
| Employees: | 145 | |||
| Issuer's Law Firm: | Mayer, Brown & Platt |
| Bank's Law Firm: | Willkie Farr & Gallagher |
| Auditor: | Price Waterhouse |
Dollar amounts in U.S. millions except for per share data | |||||
| 6 Month Ending Financials | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Audited Income | Balance Sheet | ||
| 12/31/96 | 6/30/97 | 6/30/96 | 6/30/97 | ||
| Revenue: | $13.24 | $8.07 | $5.38 | Assets: | $14.57 |
| Net Income: | -$18.18 | -$7.63 | -$9.25 | Curr Assets: | $7.15 |
| EPS: | -$2.98 | -$1.25 | -$1.51 | Liabilities: | $17.04 |
| Prior EPS: | Curr Liab: | $17.04 | |||
| Cash Flow/Oper: | -$18.28 | -$7.08 | -$8.06 | Equity: | -$2.47 |
| Cash Flow/Fin: | $12.42 | $7.76 | $2.37 | Cash: | $0.17 |
| Cash Flow/Inv: | $5.65 | -$0.50 | $5.53 | Working Cap: | -$9.89 |
| Use of Proceeds |
| The proceeds from the proposed offering will be used to accelerate product development, expand sales and marketing capability, acquire complementary technologies and intellectual property rights as opportunities arise and repay indebtedness. |
| Name of Shareholder | % Owned Before | % Owned After |
| Amoco Corporation | 1.00 | 0.63 |